2021 KUMC Virtual Multidisciplinary Oncology Review
KUMC Updated Data on mCRPC: Cabazitaxel vs. Abiraterone/Enzalutamide, Lu-177 vs. Cabazitaxel, Olaparib vs. Enzalutamide/Abiraterone, Rucaparib for BRCA Alterations
Login to view comments.
Click here to Login